The second topic of discussion relating to this issue was the timing of TKI initiation: immediately on initiation of induction therapy, or starting on day 15 as in the EsPhALL protocol for BCR::ABL1-positive ALL. This evidence concerns the gene BCR and acute lymphoblastic leukemia.